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Background: Workers with rheumatoid arthritis (RA) often experience restrictions in functioning at work and
participation in employment. Strategies to maintain work productivity exist, but these interventions do not involve
the actual workplace. Therefore the aim of this study is to investigate the (cost)effectiveness of an intervention
program at the workplace on work productivity for workers with RA.
Methods/design: This study is a randomized controlled trial (RCT) in specialized rheumatology treatment centers in
or near Amsterdam, the Netherlands. Randomisation to either the control or the intervention group is performed at
patient level. Both groups will receive care as usual by the rheumatologist, and patients in the intervention group
will also take part in the intervention program. The intervention program consists of two components; integrated
care, including a participatory workplace intervention. Integrated care involves a clinical occupational physician,
who will act as care manager, to coordinate the care. The care manager has an intermediate role between clinical
and occupational care. The participatory workplace intervention will be guided by an occupational therapist, and
involves problem solving by the patient and the patients’ supervisor. The aim of the workplace intervention is to
achieve consensus between patient and supervisor concerning feasible solutions for the obstacles for functioning at
work. Data collection will take place at baseline and after 6 and 12 months by means of a questionnaire. The
primary outcome measure is work productivity, measured by hours lost from work due to presenteeism. Secondary
outcome measures include sick leave, quality of life, pain and fatigue. Cost-effectiveness of the intervention
program will be evaluated from the societal perspective.
Discussion: Usual care of primary and outpatient health services is not aimed at improving work productivity.
Therefore it is desirable to develop interventions aimed at improving functioning at work. If the intervention
program will be (cost)effective, substantial improvements in work productivity might be obtained among workers
with RA at lower costs. Results are expected in 2015.
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Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic inflammation of the joints [1].
Fatigue, stiffness and pain are prominent symptoms. RA
has a fluctuating and chronic progressive course and
may result in loss of function of the joints [2].
In northern Europe, the prevalence of RA is estimated
at 6.6 per 1000 [3]. In the Netherlands, the prevalence
was estimated at 7 per 1000 in men, and 11 per 1000 in
women in 2007 [4]. The work status of RA patients
affects the costs for society for RA [5]. In a review of
Lundkvist et al. (2008), the economic impact of RA on
society was reviewed. Overall, the mean annual costs per
patient were estimated at around 13500 Euros in Europe.
Besides medical costs and drugs, which represent for
about one-third of these costs, productivity losses ac-
count for a substantial part of the total costs of RA
(32%). Other costs include informal care costs, and non-
medical costs such as formal home help [3].
The International Classification of Functioning, Dis-
ability and Health (ICF, Figure 1) describes participation
as all aspects concerning activities (execution of a task
or action) and participation in daily life (involvement in
a life situation) [6]. RA patients often experience restric-
tions in participation in employment. A Dutch cohort of
RA patients showed that RA patients have higher work
disability rates when compared to the Dutch population;
after a mean disease duration of 4.3 years, RA patients
had a 2.14 risk of being work disabled [7]. In another
Dutch cohort of patients with early arthritis (EAC), 19%
of the patients became work disabled over a period one
year before and one year after entering the EAC [8]. In a
review study, it was reported that 66% of employees with
RA reported work loss due to RA in the past year, with
a median duration of 39 days [9]. RA patients reported
to make adaptations in their work environment in anFigure 1 International classification of functioning, disability and heaattempt to continue working, but were still afraid of los-
ing their job [10].
The health care available for Dutch RA patients is
strictly separated into an occupational health system and a
curative health system. Communication between medical
specialists and occupational physicians/therapists is poor
and the patient often has to deal with conflicting advises
[11]. Consultations with the rheumatologist do not con-
cern work and work-related problems the patient might
be facing and furthermore, usual care does not include
consultation with the occupational physician; patients only
visit the occupational physician in case of sick leave [12].
The current health care for RA patients is mainly focused
on treating the health condition with little attention for
environmental and personal factors, while, in light of the
ICF model, attention for environmental and personal fac-
tors is crucial in improving participation.
The Dutch Health Council stated that there is a strong
need for multidisciplinary recommendations for (re-
sumption of) work activities in chronic diseases [13].
Previous research on the effect of integrated care pro-
grams on work participation in chronically ill patients
has shown that integrated care might increase work par-
ticipation [14,15]. In general, suboptimal care by lack of
communication may lead to long-term absenteeism from
work and permanent disability, which are associated
with high costs [13,16].
Because of the need for recommendations for work ac-
tivities in chronic diseases and the fact that involving ex-
ternal factors (i.e. the worksite) might make a difference,
this study aims to develop and implement a structured,
well-coordinated intervention program intended to coord-
inate the clinical care and occupational care at the work-
site and thereby support work participation of workers
with RA. Integrating clinical and occupational care will
lead to one treatment goal for the involved caregivers,lth [6].
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form one treatment advise for the patient, so the patient
does not have to deal with conflicting advises. In contrast
to previous studies, the current intervention will be exe-
cuted at the worksite, involving the patients’ supervisor
and the primary aim is to maintain and increase work
productivity instead of health outcomes. The workplace
intervention, which is based on participatory ergonomics,
will be tailored to the individual worker, making it possible
to address issues such as workload, decision latitude, com-
munication between employee and supervisor, and redu-
cing barriers at the workplace. Furthermore, the current
study focuses on improving and maintaining work prod-
uctivity, instead of job loss.
The aim of this paper is to describe the design of a ran-
domized controlled trial (RCT) comparing the interven-
tion program with usual care for patients with RA. The
first objective of this study is to evaluate the (cost)effect-
iveness of the intervention program on work productivity,
measured by hours lost from work due to presenteeism.
The second objective of this study is to evaluate the
process of implementation (experiences, acceptance, bar-
riers, and facilitators) of the intervention program.Methods
Organization of the study
The design of this study is an RCT with a follow up of
one year. Patients will be recruited from Reade (a specia-
lized rheumatology center, formerly the Jan van Breemen
Institute), Amsterdam, the outposts of Reade, and the
department of rheumatology of the VU University Med-
ical Center, Amsterdam, the Netherlands.
The Medical Ethics Committee of the Slotervaart Hos-
pital and Reade, and the VU University Medical Center,
Amsterdam, the Netherlands approved the study design,
protocols, procedures, and informed consent. Participa-
tion is voluntary and all participants will sign informed
consent. Towards the involved stakeholders (employees,
supervisors and all involved caregivers) the study is
entitled the “Care for Work” study.Participants
The population consists of RA patients (18–64 years)
who have visited a rheumatologist of one of the partici-
pating hospitals during the last year. Eligible patients are
diagnosed with RA, and have a paid job (paid-employ-
ment or self-employed) for at least 8 hours per week.
Furthermore, eligible patients experience difficulties in
functioning at work. Patients will be excluded from the
study in case of severe comorbidity that will hamper
compliance to the protocol, when unable to read or
understand Dutch language, and when taking more than
3 months sick leave at time of inclusion.Eligible patients will receive an information letter about
the project from their own rheumatologist three weeks be-
fore the consult with the rheumatologist. This letter
includes a reply card which patients can use to point out
whether they want to participate in the study or not.
Patients who return the reply card and indicate to be will-
ing to participate in the study are contacted by the re-
searcher by telephone. In this contact, the researcher
provides additional information about the implications of
participation and checks the eligibility of the patient based
on the inclusion and exclusion criteria. If a patient meets
all selection criteria, the researcher plans a face-to-face ap-
pointment with the patient, preferably immediately before
or after the consultation with the rheumatologist. When
this is not possible, the face-to-face appointment is
planned on a different date. In addition, patients are
offered the opportunity of a home visit. During the face-
to-face appointment, the patient will be asked to sign
informed consent, and complete the baseline question-
naire. Furthermore, randomisation will be performed.Randomisation
Randomisation to either the intervention group or control
group will be performed on patient level. To prevent un-
equal randomisation, patients will be pre-stratified by 3
prognostic factors; sex, whether the patient performs
heavy physically/mentally demanding work or light phys-
ically/mentally demanding work, and the number of work-
ing hours per week. To determine whether a patient
performs physically/mentally heavy or light work, a classi-
fication of De Zwart (1997) will be used, which is based
on the subdivision of all occupational classes in the Neth-
erlands [17]. The third stratification factor is the number
of working hours per week. Work hours will be divided
into high and low; high represents 20 work hours per
week or more, and low represents less than 20 work
hours. Randomisation will be performed using minimisa-
tion [18]. Minimisation was chosen because this method
makes it possible to balance groups for several prognostic
factors, even in small samples [18,19]. Minimisation aims
to ensure treatment arms are balanced with respect to
predefined patient factors as well as for the number of
patients in each group. Minim is a software program
based on the minimisation method, which will be used for
treatment allocation [20]. The result of the randomisation
will be kept in a sealed envelope before handing the enve-
lope to the participant.Interventions
All participants will receive usual rheumatologist-led
care. The participants in the intervention group will also
take part in the intervention program. The intervention
program consists of two components which complement
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workplace intervention. Both are described below.Intervention component 1: Integrated care
Integrated care will be provided based on a case man-
agement protocol which will be executed by a multidis-
ciplinary team. This team consists of a trained clinical
occupational physician (who will act as care manager), a
trained occupational therapist, and the patients’ own
rheumatologist and occupational physician.
The care manager has an intermediate role between
clinical and occupational care. He is responsible for the
planning and coordination of care, and for communica-
tion between all members of the multidisciplinary team,
the patient’s supervisor and general practitioner.
The patient will visit the care manager within one
week after randomisation. The care manager starts with
history taking and physical examination. History taking
aims to identify functional limitations at work and fac-
tors that could influence functioning at work. By the end
of the first consultation, the care manager proposes a
treatment plan. If the patient agrees with the plan, the
care manager will contact the patients’ rheumatologist in
order to advise the plan for adjustments at work. When
the patients’ rheumatologist agrees with the plan, the
care manager will send the treatment plan to the other
members of the multidisciplinary team. If the rheuma-
tologist does not agree with the treatment plan, the careWeek Care manager (COP) OT
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development of treatment 
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concerning treatment plan 
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Figure 2 Time scheduling of the multidisciplinary intervention progra
OP = occupational physician; WI = workplace intervention.manager will have contact with the rheumatologist, dis-
cuss the treatment plan and achieve consensus.
Another task of the care manager is to coordinate com-
munication between the members of the multidisciplinary
team. This will occur during a conference call with all
members, or by sending coded emails to all members. The
patient will visit the care manager again after 6 and
12 weeks to evaluate and if necessary adjust the treatment
plan. Figure 2 depicts the flow of the intervention program.
Intervention component 2: Participatory workplace
intervention
The workplace intervention concerns workplace adapta-
tions and is based on active participation and strong
commitment of both the patient and supervisor. The
workplace intervention is based on methods used in
participatory ergonomics [12,21,22]. The workplace inter-
vention will be coordinated by the occupational therapist,
and executed by the patient, the patients’ supervisor, and
other potential stakeholders (e.g. a human resource
manager). The aim of the workplace intervention is to
achieve consensus between patient and supervisor con-
cerning feasible solutions for the obstacles for functioning
at work. After consensus, the occupational therapist, pa-
tient, and supervisor agree on a plan of action. Responsi-
bility for implementing the plan of action is put on the
patient and the patients’ supervisor’s account as much as
possible. For this intervention, two occupational therapists
will be trained by an expert to coordinate the workplaceRheumatologist Patient’s OP
2ni
t about 
are 
ient, 
r 
ort to 
r, 
m. COP = clinical occupational physician; OT = occupational therapist;
Table 1 Steps of the workplace intervention protocol
Step Workplace intervention protocol
1 Within 2 weeks after the patient visits the care manager, the OT makes an appointment by telephone with the patient and the patient’s
supervisor for the first visit of the workplace intervention protocol.
2 First visit consists of:
1. Patient’s workplace observation and inventory and ranking of patient’s tasks and obstacles for functioning at work by the patient.
2. Inventory and ranking patient’s tasks and obstacles for functioning at work by the patient’s supervisor.
3. Patient, patient’s supervisor and OT brainstorm and discuss solutions to clear the obstacles for functioning at work.
3 Within two days after the OT has visited the workplace, the OT reports about all solutions and actions in a report to the patient, the patient’s
supervisor, and the care manager.
4 An optional worksite visit to give additional instructions or training to the patient will take place if necessary. The moment of instruction
depends on whether adjustments on the worksite have to be made first.
5 Four weeks after the first visit, an evaluation will take place by telephone between the patient and OT concerning the implementation of
solutions agreed upon. If necessary, a stakeholder has to be found for further support of improvements.
6 Within two days after the telephone evaluation, a final report is sent to the care manager to report the progress of the protocol.
OT, occupational therapist.
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intervention.
Outcome assessment and data collection
Outcome measures
Primary outcome The primary outcome of this study is
productivity, measured by hours lost from work due to
presenteeism. Presenteeism is the problem of being on
the job but, because of medical conditions, not being
able to fully function. Presenteeism will be measured by
means of the Work Limitations Questionnaire (WLQ)
[23]. Based on 25 items, a score will be calculated which
presents the percentage of productivity loss. This score
will be multiplied by the number of work hours per
week, leading to an estimation of the hours that a pa-
tient was not fully productive. The WLQ consists of four
dimensions; physical demands (Cronbach’s alpha 0.93),
time management (Cronbach’s alpha 0.95), mental-
interpersonal demands (Cronbach’s alpha 0.97), and out-
put demands (Cronbach’s alpha 0.96) [24]. Presenteeism
will be measured at baseline, and after 6 and 12 months.
The recall period of the WLQ is 2 weeks. The validity
and reliability of the WLQ concerning RA have been
shown in several publications [24-26].
Secondary outcomes Sick leave will be measured with
modules C and D of the Productivity and Disease Ques-
tionnaire (Prodisq) [27]. The Prodisq is developed based
on the Quantity and Quality (QQ) method and provides
a reliable and valid tool for measuring quantity and qual-
ity of work on a daily basis [28].
Quality of life will be measured by means of the
RAND-36 and EQ-5D-5L [29,30]. The RAND-36 con-
sists of 8 subscales, namely physical functioning, role
limitations due to physical problems, social functioning,
bodily pain, general mental health, role limitations due
to emotional problems, vitality, and general health per-
ceptions [31]. The EQ-5D-5L is an improved version ofthe Euroqol (EQ-5D). In contrast to the Euroqol, the
EQ-5D-5L has 5 levels of severity in 5 dimensions, in
stead of 3 levels of severity in 5 dimensions, which
improves the instrument’s sensitivity [30]. The Euroqol
has been validated in a population of RA patients [32].
Pain and fatigue will be measured with single items
using visual analogue scales (VAS) [33,34]. Studies have
shown that a single item VAS for fatigue and pain per-
forms as well as or better than longer scales in respect
to sensitivity to change [34,35].
The subscale ‘supervisor social support’ of the Job Con-
tent Questionnaire (JCQ) will be measured as effect [36].
The RA Work Instability Scale (RA-WIS) will be used
to measure work instability [37,38]. The RA-WIS con-
sists of 23 statements which are answered by ‘yes’ or
‘no’. The RA-WIS can be scored in three bands by
counting the number of items answered by yes. A score
less than 10 indicates low work instability, indicative of
low risk of work disability. Scores in the range of 10–17
indicate moderate work instability. Scores above 17 are
high scores of work instability and these individuals can
be considered at high risk of work disability.
Prognostic measures All prognostic measures will be
collected at baseline. Sociodemographic data will be col-
lected such as age, sex, education, working hours per
week, and job description. Medication used will be col-
lected from the patient records. Furthermore, daily func-
tioning will be measured at baseline, by means of the
Health Assessment Questionnaire (HAQ) which is a reli-
able, valid questionnaire widely used in RA research
[39]. In addition the Disease Activity Score (DAS28) will
be included as a prognostic factor. The DAS28 is
assessed as a part of usual care by the rheumatologist
and will be obtained from the patient records.
Psychosocial job characteristics will be examined by
using the JCQ. The following subscales will be used as
prognostic measures; Decision authority; Psychological
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support [36].Process evaluation The process evaluation aims to
examine experiences with the intervention program. The
process evaluation will be carried out using both quanti-
tative and qualitative techniques; a short questionnaire
will be composed and interviews will be conducted after
6 months follow up. Data will be collected from the par-
ticipants, the participants’ supervisors, and the health
professionals involved (clinical occupational physician,
occupational therapist and rheumatologist).
Process measures for the process evaluation include
compliance to the intervention, realisation of the advices
and adjustments at work, and satisfaction with the inter-
vention. We will focus on the reach (part of the target
group that participates), dose delivered (efforts of the
health professionals), dose received (extent to which the
patient has put effort in the intervention), and fidelity
(extent to which the intervention was delivered accord-
ing to the protocol). The process measures that will be
examined in the process evaluation will be based on the
model of Linnan and Steckler (2002) [40].Cost-effectiveness evaluation Cost-effectiveness of the
intervention will be evaluated from the societal perspec-
tive whereby the costs and benefits will be captured inde-
pendently of those who bear the costs and those who
receive the benefits. Health care costs, productivity costs
and costs in other sectors will be measured and valued.
Health care costs comprise costs directly related to the
provision of health care, such as costs for primary and sec-
ondary care, but also costs for drugs and alternative treat-
ments. The health care costs will be calculated by using
tariffs for the costs of health care professionals based on
the cost calculation guidelines for health care in the Neth-
erlands [41]. The prices of prescribed drugs will be based
on Daily Defined Dosage (DDD) taken from the Royal
Dutch Society for Pharmacy [41]. The direct non-health
care costs are calculated by using the information
obtained from the cost questionnaires and shadow prices.
The costs directly related to the development and imple-
mentation of the intervention will be registered. Product-
ivity costs are not related to health care, but are costs in
paid labour as a consequence of sickness, sick leave, dis-
ability of a productive person. The most important prod-
uctivity costs will be measured in terms of lost
productivity: presenteeism, absenteeism and compensa-
tion mechanisms. Lost productivity will be calculated by
using the Friction costs method which basically multiplies
the days of production loss till replacement by the average
day wage [41]. For the latter method, the Dutch guideline
for economic evaluation is used [41].Detailed information concerning the methods for eco-
nomic evaluation can be found in the article by Noben
(2010) [42].
Sample size The sample size calculation is based on the
primary outcome of this study, which is productivity at
work, measured by hours lost from work through pres-
enteeism, measured by the Work Limitations Question-
naire (WLQ). We assume that a difference in the score
of two hours lost per two weeks due to presenteeism is a
relevant difference. This is based on a recent study,
where an average number of four lost hours per two
weeks (SD: 3.9) was measured among patients with RA
by using the WLQ [43]. A two hour per two weeks dif-
ference implies a moderate standardized effect of 0.5.
Power analysis revealed a sample size of 71 participants
per group, assuming a dropout rate of 15%. This implies
that 142 patients will have to be included in total. The
difference in score of the WLQ of two can be detected
with a power (1-beta) of 0.80 and an alpha of 0.05.
Blinding Patients, therapists and researchers cannot be
blinded for the allocated treatment after randomisation.
Treatment allocation takes place after the informed con-
sent form is signed, and the baseline questionnaire is
filled out. It is not likely that the researcher or care pro-
viders will influence the way participants fill out the fol-
low up questionnaires, since these will be sent either by
mail or by email. All participants will receive their own
personal code, based on the treatment center they attend
and a run-up number. The research assistant will put all
data in the computer by the personal code. Therefore,
the analysis of the data by the researcher will be blind.
Co-interventions and compliance The use of co-
interventions cannot always be avoided during the
intervention period. Asking patients and care givers
independently about all interventions applied will
assess the compliance to the intervention program
evaluated in this study. Information about all treat-
ments and co-interventions received by patients in
both the intervention as well as the control group will
be collected by means of questionnaires at 6 and
12 months follow-up.
Statistical analysis
Effect evaluation The outcomes of the questionnaires
will be compared between both groups at baseline and
at follow-up. All analyses will be performed at patient
level according to the intention to treat principle.
First, to examine the success of randomization, prog-
nostic factors will be compared between the two groups by
Student T tests and Chi square tests. In case of
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prognostic factor acts as a confounder or effect modifier.
The primary independent variable in the analyses will
be the treatment group: intervention or usual care). The
primary dependent variable is work productivity. Two
analyses will be performed: a) linear mixed model with
the outcome variable measured at follow-up as the
dependent variable, adjusted for the outcome measured
at baseline, and b) an analysis as above but adjusted for
potential covariates (e.g. age, sex, type of work, time
from diagnosis RA).
Effects of the intervention will be checked for effect
modification (e.g. sex, HAQ score, time from diagnosis
RA). All analyses will be performed with SPSS 18.0
(SPSS Inc. Chicago, Illinois, USA). Outcome variables
will be assessed at a significance level of 0.05.
In order to assess whether protocol deviations have
caused bias, the results of the intention-to-treat analyses
will be compared to per-protocol analyses. Only those
patients who complied fully with the intervention proto-
col will be included for the per-protocol analyses.
Cost-effectiveness evaluation Bootstrapping will be
used for comparison of mean direct, indirect and total
costs between the two groups. Confidence intervals will
be obtained to estimate the uncertainty surrounding
these costs differences. Incremental cost-effectiveness
ratios (ICER) are calculated by dividing the difference
between the mean costs of the intervention by the differ-
ence between the mean effects of the intervention to in-
dicate whether the additional costs needed for the
intervention gain at least one extra unit of effect com-
pared to usual care. The bootstrapped cost-effect pairs
are graphically presented in a cost-effectiveness plane.
The calculated ICER is compared with a threshold on
the graph which indicates the maximum amount society
is willing to pay for the intervention/outcome measure.
Acceptability curves are calculated in order to show the
probability of the intervention being cost-effective at a
specific ceiling ratio. Furthermore, sensitivity analyses
will be performed to process the robustness of the eco-
nomic evaluation by examining changes in results when
key variables are varied over a specific range (change
cost prices, or calculation methods for (in)direct costs).
Discussion
In this study, the cost effectiveness of an integrated care
program including a participatory workplace intervention
on work productivity for workers with RA will be investi-
gated. In contrast to previous initiatives, the current inter-
vention will be executed in a clinical and occupational
setting. By integrating both aspects of health care, one
treatment goal will be formed, namely improving work
productivity. Furthermore, the workplace intervention willbe tailored to the specific needs of a worker, making it
possible to address difficulties the worker is experiencing
while at work.
Comparison with other studies
Work disability rates are higher in patients with RA as
compared to the general Dutch population [7]. The work
status of patients with RA affects the costs for society
for RA [5]. As described before, Lundkvist (2008) shows
that productivity losses account for one third of the total
costs of RA [3]. These data highlight the need for inter-
ventions aimed to improve and maintain work product-
ivity and hence, prevent job loss.
In 2002, a systematic review was performed to de-
scribe the effectiveness of vocational rehabilitation pro-
grams for patients with chronic rheumatic diseases [44].
This review identified six studies, all uncontrolled. Five
of six vocational rehabilitation programs showed a
marked positive effect on work status, but evidence for
the benefit of these interventions is limited, due to
methodological shortcomings.
A recent RCT in the Netherlands compared a multidis-
ciplinary job-retention vocational rehabilitation program
with usual outpatient care [45,46]. The multidisciplinary
vocational rehabilitation programme aimed to guide
patients and adapt an intervention to the specific needs of
the patient. The basic assessment of the patient was per-
formed by a rheumatologist. No differences were found
between the two groups regarding the proportion of
patients having lost their job at any time point.
The study of Allaire (2003) showed a significant delay
of job loss in the intervention group compared to the
control group [47]. The intervention consisted of three
components; job accommodation, vocational counselling
and guidance, and education and self-advocacy. The
intervention was delivered by a rehabilitation counsellor
employed by the study.
These examples show the need for intervention pro-
grams aimed to improve work productivity and prevent
job loss, but up till now, no effective intervention pro-
grams on work productivity have been identified. What
we aim to do differently in the current study is that the
worksite and the patient’s supervisor are involved in the
intervention, because previous initiatives that did not in-
volve the worksite were not effective. The current inter-
vention is based on the interventions evaluated in the
studies of Lambeek (2010) and van Oostrom (2010)
[14,48]. Both studies showed a positive effect of the
workplace intervention.
Methodological considerations
A weakness of this study might be that all data is self
reported. No objective data will be collected concern-
ing sick leave, and objective data concerning work
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about whether self reported data is reliable. However,
several recent studies report that similarity between self
reported data and data from for example a national in-
surance authority is high, and that self reported data is
justified in research [49,50]. Despite the accuracy of self
reported data, there is still a chance of recall or informa-
tion bias. Because this study is a randomized controlled
trial, we expect recall bias to occur to some extent in
both treatment arms. Therefore, recall bias will not lead
to an overestimation of study results. Besides this, we in-
vestigate differences in time for our primary outcome. It
is likely that an over- or underestimation will be the
same on all three time points; therefore, delta will not
change. Our primary outcome, work productivity, is
measured by a valid measurement tool [24]. The WLQ
has been validated among patient with osteoarthritis.
The internal validity of this RCT might be affected by
the fact that due to our study design and the character of
the workplace intervention, blinding of patients and health
care providers is not possible. A potential source of bias is
the difference in attention patients receive, also called the
Hawthorne effect [51]. The Hawthorne effect refers to the
methodological effect in field experiments that patient’s
knowledge that they take part in an intervention modifies
their behaviour from what it would have been without the
knowledge. In this study, patients in the intervention
group will receive more attention than patients in the
usual care group, which might lead to an overestimation
of the effect of the intervention program. Although the
Hawthorne effect cannot be prevented completely, the
control group in this RCT continues to receive usual care.
Therefore, they will not receive no attention at all.
A strength of this study is that, in contrast to previous
studies, the intervention is executed at the workplace.
As described by the ICF model, environmental factors
will be involved in order to maintain and improve work
productivity for workers with RA. Involving the super-
visor in the intervention and adapting solutions for
obstacles for functioning at work to the specific needs of
patient and supervisor, is a substantial difference when
compared to previous initiatives for workers with RA.
Another strength of this study is that it builds on posi-
tive experiences of previous successful studies in other
settings and populations [14,48].
Impact of the results
Support for workers with RA to improve work productiv-
ity and maintain paid work is important for the individual
workers, employees, and society. The previous study of
Lambeek et al. (2010) showed a major improvement on
return to work for workers with chronic low back pain
who are completely or partially sick listed, by an interven-
tion program consisting of integrated care, a participatoryworkplace intervention and graded activity. The solutions
negotiated during the participatory workplace intervention
were highly implemented. As described before, the current
study is based on the intervention used in the study of
Lambeek et al. (2010). High implementation of solutions
negotiated during the participatory workplace intervention
might lead to a substantial improvement in the work
productivity of workers with RA, and the chances of im-
plementation in usual care will be higher. When cost ef-
fective, it will be worth considering the integrated care
intervention for usual care for workers with RA who come
across difficulties at work.
Results are expected in 2015.
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